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P olonius: The best actors in the world, either for Tragedie, Comedie, Historie, Pastorall: Pastoricall-
Comicall-Historicall-Pastorall: Tragical-Historical: Tragicall-Comical-Historicall-Pastorall: Scene 
indivible, or Poem unlimited. Seneca cannot be too heavy, nor Plautus too light, for the law of Writ, 
and the Liberty. These are the only men.1
The problem of stage III non–small-cell lung cancer (NSCLC) is one of the most 
interesting in all of thoracic oncology. The issues arise from the relative inaccessibility 
of the mediastinum to biopsy,2,3 the great heterogeneity of the population (ranging from 
patients with T3N1M0, through those with T1–3N2M0, and since the American Joint 
Committee on Cancer 7th edition system, patients with T4N0–1M0 disease),4 and the 
diversity of potential treatment options.5 Even within the more homogeneous group, those 
with stage IIIA on the basis of N2 disease, there remains great heterogeneity because of the 
range of T-categories included, and differences in the amount of N2 disease.6
At one extreme, patients with unexpected N2 disease that is detectable only after 
pathology examination of the resection specimen, after false-negative standard preoperative 
staging tests, have a prognosis very different from those with bulky multi-station lymph-
adenopathy, who reside at the other end of the spectrum.6,7 Matters are further complicated 
by the varying levels of histologic confirmation of N2 disease in the clinical trials in this 
population. Therefore, interpreting clinical trials of N2 NSCLC demands careful attention 
to the population selected by the eligibility criteria, and the final results always seem to pose 
more questions than they answer.
And clinical trials there have been. In the past three decades, at least seven major 
prospective, randomized multi-institutional trials and two meta-analyses have attempted to 
shed light on questions that swirl around the optimal treatment of N2 NSCLC. In the 1990s, 
Rosell et al.8 and Roth et al.9 independently demonstrated that the combination of preoperative 
chemotherapy and surgery (Polonius might say, “tragical-historical”) was superior to surgery 
alone; Dillman et al.10 demonstrated that the combination of chemotherapy and radiation 
(historical-pastoral?) was superior to radiation alone for patients who could not undergo 
surgery; and Furuse et al.11 reported the superiority of concurrent combined modality 
chemoradiotherapy over sequential therapy. In the next decade, the International Adjuvant 
Lung Trialists12 and the Lung Adjuvant Cisplatin Evaluation meta-analysis13 demonstrated 
that postoperative adjuvant chemotherapy improves survival of patients with N2 disease; and 
an update Postoperative Radiation Therapy meta-analysis remained ambivalent about the 
value of postoperative adjuvant radiation therapy in patients with N2 disease.14 The unifying 
theme of these studies was the superiority of multimodal therapy over unimodal therapy in 
patients who are fit for such treatment (“Scene indivible” indeed!).
The question of the optimal multimodal therapy has been addressed by two major 
randomized controlled trials. Van Meerbeeck et al.15 compared outcomes in patients who 
were randomized, after induction chemotherapy, to either definitive radiation therapy 
or surgery, and found no difference in survival. However, an unplanned analysis of the 
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resection cohort suggested that patients with complete resec-
tion short of pneumonectomy, and clearance of N2 disease 
after induction chemotherapy, might benefit more from sur-
gery.15 Unfortunately, 47% of patients in this study received 
pneumonectomy, including 25% on the right side. Albain 
et al.16 compared the outcomes of recipients of concurrent 
chemoradiotherapy, who were randomized to surgery (trag-
ical-comical-historical-pastoral) or no surgery and found no 
difference in survival between the two arms, suggesting that 
the addition of surgery to chemoradiation therapy provides 
no additive benefit. However, in an unplanned exploratory 
matched subset analysis of trimodal versus bimodal therapy, 
in which recipients of lobectomy were analyzed separately 
from those who received pneumonectomy, survival was sig-
nificantly superior with trimodality therapy using lobectomy, 
whereas, it was significantly inferior when pneumonectomy 
was the surgical option used for trimodality therapy.
These studies raise several interesting questions: “Is 
trimodality therapy the best treatment when the surgeon is 
sure he will not have to resort to pneumonectomy?,” “Is the 
addition of surgery preferable in patients with clearance of 
mediastinal lymph node disease?,” and, “Would trimodal-
ity therapy be better in carefully selected patients at centers 
with low postpneumonectomy mortality?”17 These questions 
cannot be answered with current evidence, they are subject to 
personal belief, institutional bias, and midrashic interpretation 
of the data.
Against this background, we come to the original sub-
mission by Berry et al.,18 which gives a retrospective review of 
all resections for N2-positive NSCLC in the U.S. Surveillance, 
Epidemiology, and End Results program (SEER)-Medicare 
database, a linkage of directly abstracted cancer registry data 
(SEER) with coded payment records from Medicare, a U.S. 
national health care payer that predominantly covers U.S. resi-
dents aged 65 years and above, and useful in providing infor-
mation on practice patterns and outcomes in the elderly.19 The 
authors’ stated objectives were to examine the pattern of care 
for IIIA (N2) NSCLC in the elderly, and to test the hypothesis 
that nonclinical characteristics play an important role in the 
use of surgery.
To address these objectives, they reviewed 2958 eli-
gible patients in the SEER-Medicare database, who received 
resections from 2004 to 2007. They found a heterogeneity of 
treatments: 52% had combined modality therapy, 30% had 
unimodal therapy, 18% had no treatment; 73% had some sort 
of definitive local therapy (radiation or surgery) in combina-
tion or unimodal fashion. Somewhat surprisingly (for this era, 
given the state of the data at the time), 13% received radia-
tion therapy only, 9% had chemotherapy alone, and 7% had 
trimodality therapy. The factors most strongly associated with 
the choice of surgery were predictable—age and T-category. 
Examination of their hypothesis about the impact of non-
clinical characteristics on the use of surgery, revealed sex and 
socioeconomic status (median residential income) as unex-
pected, albeit weak, associated factors.
The study by Berry et al.18 is interesting because the 
information about patterns of care can serve as a useful 
foundation on which to construct future examinations of the 
evolution of practice patterns in the wake of the seven land-
mark trials and two meta-analyses cited.8–16 There is much that 
is reassuring in their findings, but also much to be disturbed 
by. On the positive side, it is encouraging that the clinicians 
seemed to have acted appropriately with the evidence before 
them. Majority use of multimodality therapy is encouraging, 
as is the seeming tendency to triage for or against surgery on 
the basis of appropriate clinical factors.
Although the authors raise the issue of racial and socio-
economic disparities in the choice of surgery, there is not much 
in this particular analysis to go on, at least by their multivari-
ate analysis, which suggests rather, that the nonclinical factors 
are probably linked and of marginal impact. No surprise here, 
given that the impact of demographics on health care dispari-
ties would have been significantly dispersed by the selection 
criteria—these patients by definition had health insurance 
(Medicare). The apparently higher survival rate of patients 
who had surgery most likely indicates that factors (advanced 
age, limited pulmonary function, poor overall performance 
status, more extensive tumors, etc.) militating against surgery, 
also drove the higher mortality of the nonsurgery patients. 
More reliable evidence from the randomized controlled trials 
cited above must temper any suggestions in this report of a 
clear superiority of surgery.
The most disturbing aspects of this report come from 
the pattern-of-care analysis. Eighteen percent of patients 
received no treatment, 30% received unimodal care, and 
40% to 48% (give or take the 8% who had surgery only) 
received no attempt at curative therapy. Is this evidence 
of the frail condition of these patients, a sense of nihil-
ism about the value of treating patients with lung cancer, 
the usual delay of evidence dissemination and implemen-
tation (the Roth, Rossell, and Dillman studies all having 
been published in high-profile journals in the 1990s; the 
current study cohort was treated in the 21st century), or is 
it some other factor? The same range of concerns applies to 
the infrequent use of invasive staging tests to confirm N2 
disease, especially given the prior report of Farjah et al.20,21 
working on this same population, but in a partially overlap-
ping era.
Lung cancer care is emerging from the dark ages 
into a period of light. The advent of screening, minimally 
invasive means of accessing the mediastinum to improve 
clinical nodal staging, minimally invasive surgical resection 
techniques that limit the morbidity of surgery, thereby 
expanding the candidate population, improvements in 
supportive care for recipients of multimodality therapy, and 
the incoming cascade of targeted therapies augur well for 
the future. We must not, like Prince Hamlet, “defy augury.” 
We must communicate our sense of optimism to the greater 
community to increase use of curative-intent therapy. The 
study by Berry et al.18 will serve as a useful template for 
future trend analyses of the pattern of care. As knowledge of 
the value of multimodality management expands, we hope 
to see a trend toward more assertive use of multimodality 
staging and treatment for this most fascinating subset of 
patients who are frighted with the peril of mortality, yet 
sustain a real potential for cure.
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